New horizons: antiretroviral therapy in 1997.
Exciting advances in basic and clinical science brought a new strategy for antiretroviral therapy and new hope to people living with HIV in 1996. There are now three major categories of antiretroviral agents available for clinical use. All require replicating virus, and none are virucidal. The goal of antiretroviral therapy is a significant and prolonged reduction of the amount of actively replicating HIV (viral load). Carefully chosen combinations of antiretroviral drugs significantly reduce HIV load and are likely to extend life. However, not all patients respond to highly active antiretroviral therapy (HAART), and, for those who do, adjustment to demanding regimens and management of side effects may be difficult. The development of drug resistance is a serious concern, because resistance is associated with rising viral loads and with poorer prognosis in advanced disease.
Williams
A B
AB
Yale School of Nursing, USA.
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003657:Decision Making; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010358:Patient Participation / Q000379:methods; D011369:Professional-Patient Relations; D011480:Protease Inhibitors / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors